Erasca (ERAS) Income from Non-Controlling Interests (2020 - 2026)
Erasca (ERAS) posted Income from Non-Controlling Interests of -$1.3 million for Q1 2026, down 6219.05% on a QoQ basis from -$21000.0 in Q4 2025, and down 695.07% year-over-year from $223000.0 in Q1 2025.
Erasca (ERAS) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Erasca's Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$1.3 million for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 695.07% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 258.35% YoY) and the FY2025 annual result came in at $223000.0, down 32.01% from the prior year.
- Income from Non-Controlling Interests was -$1.3 million for Q1 2026 at Erasca, down from -$21000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.0 million in Q3 2024 and bottomed at -$1.4 million in Q4 2024.
- A 5-year average of -$31588.2 and a median of -$21000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests tumbled 78800.0% — and 2024, when it surged 827.06%.
- Erasca's Income from Non-Controlling Interests stood at $338000.0 in 2022, then jumped by 92.9% to $652000.0 in 2023, then tumbled by 317.79% to -$1.4 million in 2024, then soared by 98.52% to -$21000.0 in 2025, then sank by 6219.05% to -$1.3 million in 2026.
- Business Quant data shows ERAS's Income from Non-Controlling Interests at -$1.3 million in Q1 2026, -$21000.0 in Q4 2025, and $234000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | - |
| 10 | Erasca | 5.90 Bn | 5.65 Bn | - | -1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.33 Mn |
| Dec 31, 2025 | -21,000.00 |
| Sep 30, 2025 | 234,000.00 |
| Jun 30, 2025 | -213,000.00 |
| Mar 31, 2025 | 223,000.00 |
| Dec 31, 2024 | -1.42 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | -287,000.00 |
| Dec 31, 2023 | 652,000.00 |
| Sep 30, 2023 | 218,000.00 |
| Jun 30, 2023 | -279,000.00 |
| Mar 31, 2023 | 527,000.00 |
| Dec 31, 2022 | 338,000.00 |
| Sep 30, 2022 | -156,000.00 |
| Jun 30, 2022 | -272,000.00 |
| Mar 31, 2022 | -789,000.00 |
| Dec 31, 2021 | -162,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -2,000.00 |